Eddingpharm Buys China Rights to Arthritis Drug from Ablynx

Eddingpharm paid $2.3 million upfront to in-license Greater China rights for an Ablynx anti-TNFa Nanobody®, a prospective treatment for rheumatoid arthritis. Ozoralizumab (TN-103) has completed a Phase II trial in which it seemed to compare favorably with the blockbuster arthritis drug Humira. This is the second agreement between Eddingpharm and Ablynx: last October, Eddingpharm and Ablynx agreed to a very similar deal for an anti-osteoporosis drug candidate. Ablynx is headquartered in Belgium. More details.... Stock Symbol: (BR:ABLX) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.